Targeting tumours with novel radiopharmaceuticals
European Pharmaceutical Review
OCTOBER 19, 2023
we must prove the effectiveness of radiopharmaceuticals through clinical trials… This has been demonstrated recently with PLUVICTO… the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer” At this moment, there is no single treatment for cancer today.
Let's personalize your content